Press Releases
Aptar Pharma Granted Exclusive License Option by Pharmaxis to Develop and Promote High Payload Dry Powder Inhaler
Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, announced that they have entered into an agreement with Pharmaxis, a clinical stage drug developer, under which Aptar Pharma has the option to acquire...
Press Releases
Moderna Announces FDA Authorization of Third Dose of COVID-19 Vaccine for Immunocompromised Individuals
Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines announced that the U.S. FDA has approved an update to the emergency use authorization for the Moderna COVID-19 vaccine (mRNA-1273) to include a third dose for immunocompromised...
Press Releases
Moderna Announces Supply Agreement with Canada for Expanded Supply of Moderna’s COVID-19 Vaccine in 2022, in 2023 and in 2024
Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced a revised supply agreement with the Government of Canada for up to 105 million doses of Moderna’s COVID-19 vaccine and its booster vaccine candidate, if authorized,...
Press Releases
Indian Immunologicals hands over first batch of COVAXIN Drug Substance to Bharat Biotech in Record Time
In order to augment the Covid 19 vaccine production capacity in our country so that a significant percentage of the population can get vaccinated at the earliest, the Central Government requested that Indian Immunologicals Ltd (IIL) and Bharat Biotech...
Clinical Trials
Valneva Initiates Further Phase 3 Clinical Trial for its COVID-19 Vaccine Candidate
Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, announced the initiation of a further Phase 3 trial (VLA2001-304) for its inactivated, adjuvanted COVID-19 vaccine...
Press Releases
Moderna and Canada Announce Collaboration to Bring mRNA Manufacturing to Canada
Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced a Memorandum of Understanding (MoU) with the government of Canada to build a state-of-the-art messenger RNA (mRNA) vaccine manufacturing facility in Canada including access to Moderna’s...
Clinical Trials
AzurRx BioPharma Adds New Clinical Trial Sites in Ukraine for Phase 2 RESERVOIR of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections
AzurRx BioPharma, Inc., a company specializing in the development of targeted non-systemic, recombinant therapies for gastrointestinal (GI) diseases, announced the completion of site initiation visits and the addition of five (5) new clinical trial sites in Ukraine for the...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
















